Medicines for all, not just the rich

March brought bad news for the HIV virus, but good news for HIV/AIDS patients, particularly those in poor countries. In the second week of the month, Merck and Co., a leading US pharmaceutical manufacturer, announced it would slash the prices of two of its antiretroviral drugs, stavudine (Zerit) and didanosine (Videx), to a combined price of US$ 1 per day and to relax its patent protection over Zerit in South Africa. The offer would allow South African-based drug companies to produce and market the drug at low cost. The surprise announcement followed protests from students at Yale University in the United States where stavudine was developed. The university holds the patent for this drug and allows Bristol-Myers Squibb to produce it on licence.

What triggered this price avalanche? Certainly, the curtain was raised on this new scenario by the dramatic February offer of the Indian drug company Cipla to sell governments a cocktail of three antiretroviral drugs for US$ 600 a year — a fraction of the US$ 10,000–15,000 price tag for this triple therapy in the United States and other countries in the west. Cipla’s offer turned the focus from country-by-country negotiations to across-the-board price reductions aimed at the poorest countries. And for sure, these reductions are part of a broader process which combines pressure from nongovernmental organizations, political will, market forces and close collaboration between the pharmaceutical industry and international organizations to make wider access to AIDS medicines a reality. Meanwhile, another Indian manufacturer of generic drugs is reportedly offering triple antiretroviral therapy for US$ 350 a year. Two leaders of the world’s pharmaceutical industry have now announced price cuts, and US$ 500 per patient per year. The price cuts would be extended, and US$ 500, respectively, per patient per year. The offer would allow South African-based drug companies to produce and market the drug at low cost. The surprise announcement followed protests from students at Yale University in the United States where stavudine was developed. The university holds the patent for this drug and allows Bristol-Myers Squibb to produce it on licence.

What triggered this price avalanche? Certainly, the curtain was raised on this new scenario by the dramatic February offer of the Indian drug company Cipla to sell governments a cocktail of three antiretroviral drugs for US$ 600 a year — a fraction of the US$ 10,000–15,000 price tag for this triple therapy in the United States and other countries in the west. Cipla’s offer turned the focus from country-by-country negotiations to across-the-board price reductions aimed at the poorest countries. And for sure, these reductions are part of a broader process which combines pressure from nongovernmental organizations, political will, market forces and close collaboration between the pharmaceutical industry and international organizations to make wider access to AIDS medicines a reality. Meanwhile, another Indian manufacturer of generic drugs is reportedly offering triple antiretroviral therapy for US$ 350 a year.

“Two leaders of the world’s pharmaceutical industry have now announced price cuts, and US$ 500 per patient per year.”

The offer would allow South African-based drug companies to produce and market the drug at low cost. The surprise announcement followed protests from students at Yale University in the United States where stavudine was developed. The university holds the patent for this drug and allows Bristol-Myers Squibb to produce it on licence.

What triggered this price avalanche? Certainly, the curtain was raised on this new scenario by the dramatic February offer of the Indian drug company Cipla to sell governments a cocktail of three antiretroviral drugs for US$ 600 a year — a fraction of the US$ 10,000–15,000 price tag for this triple therapy in the United States and other countries in the west. Cipla’s offer turned the focus from country-by-country negotiations to across-the-board price reductions aimed at the poorest countries. And for sure, these reductions are part of a broader process which combines pressure from nongovernmental organizations, political will, market forces and close collaboration between the pharmaceutical industry and international organizations to make wider access to AIDS medicines a reality. Meanwhile, another Indian manufacturer of generic drugs is reportedly offering triple antiretroviral therapy for US$ 350 a year.

“Two leaders of the world’s pharmaceutical industry have now announced price cuts, and US$ 500 per patient per year.”

The offer would allow South African-based drug companies to produce and market the drug at low cost. The surprise announcement followed protests from students at Yale University in the United States where stavudine was developed. The university holds the patent for this drug and allows Bristol-Myers Squibb to produce it on licence.

What triggered this price avalanche? Certainly, the curtain was raised on this new scenario by the dramatic February offer of the Indian drug company Cipla to sell governments a cocktail of three antiretroviral drugs for US$ 600 a year — a fraction of the US$ 10,000–15,000 price tag for this triple therapy in the United States and other countries in the west. Cipla’s offer turned the focus from country-by-country negotiations to across-the-board price reductions aimed at the poorest countries. And for sure, these reductions are part of a broader process which combines pressure from nongovernmental organizations, political will, market forces and close collaboration between the pharmaceutical industry and international organizations to make wider access to AIDS medicines a reality. Meanwhile, another Indian manufacturer of generic drugs is reportedly offering triple antiretroviral therapy for US$ 350 a year.

“Two leaders of the world’s pharmaceutical industry have now announced price cuts, and US$ 500 per patient per year.”

The offer would allow South African-based drug companies to produce and market the drug at low cost. The surprise announcement followed protests from students at Yale University in the United States where stavudine was developed. The university holds the patent for this drug and allows Bristol-Myers Squibb to produce it on licence.

What triggered this price avalanche? Certainly, the curtain was raised on this new scenario by the dramatic February offer of the Indian drug company Cipla to sell governments a cocktail of three antiretroviral drugs for US$ 600 a year — a fraction of the US$ 10,000–15,000 price tag for this triple therapy in the United States and other countries in the west. Cipla’s offer turned the focus from country-by-country negotiations to across-the-board price reductions aimed at the poorest countries. And for sure, these reductions are part of a broader process which combines pressure from nongovernmental organizations, political will, market forces and close collaboration between the pharmaceutical industry and international organizations to make wider access to AIDS medicines a reality. Meanwhile, another Indian manufacturer of generic drugs is reportedly offering triple antiretroviral therapy for US$ 350 a year.

“Two leaders of the world’s pharmaceutical industry have now announced price cuts, and US$ 500 per patient per year.”

The offer would allow South African-based drug companies to produce and market the drug at low cost. The surprise announcement followed protests from students at Yale University in the United States where stavudine was developed. The university holds the patent for this drug and allows Bristol-Myers Squibb to produce it on licence.

What triggered this price avalanche? Certainly, the curtain was raised on this new scenario by the dramatic February offer of the Indian drug company Cipla to sell governments a cocktail of three antiretroviral drugs for US$ 600 a year — a fraction of the US$ 10,000–15,000 price tag for this triple therapy in the United States and other countries in the west. Cipla’s offer turned the focus from country-by-country negotiations to across-the-board price reductions aimed at the poorest countries. And for sure, these reductions are part of a broader process which combines pressure from nongovernmental organizations, political will, market forces and close collaboration between the pharmaceutical industry and international organizations to make wider access to AIDS medicines a reality. Meanwhile, another Indian manufacturer of generic drugs is reportedly offering triple antiretroviral therapy for US$ 350 a year.
Lifestyle and Alzheimer disease — study strengthens link

African-Americans living in an industrialized US city are more than twice as likely to develop Alzheimer disease and other dementias than are Africans living in Nigeria, according to a study published in the 14 February Journal of the American Medical Association.

The ten-year study, a collaborative effort of researchers from both countries, compared the incidence rates of Alzheimer disease (AD) and other dementias in people over age 65 in Indianapolis, Indiana, in the US, and in Ibadan, Nigeria. A baseline survey identified 2147 African-Americans in Indianapolis and 2459 Yoruba residents of Ibadan who did not have dementia. Follow-up studies at 2 and 5 years found that 2.52% of the African-Americans eventually developed AD, compared to only 1.15% of the Yoruba; overall, 3.24% of the African-Americans developed any form of dementia (including AD), compared to 1.35% of the Yoruba. The rates found among the African-Americans are in the “higher range of previously published” rates, while the rates found in the Yoruba are among the lowest, reported the study’s principal investigators, Dr Hugh C. Hendrie of the University of Indiana School of Medicine in the US and Dr Adesola Ogunniyi of the University of Ibadan.

The researchers did not draw conclusions as to why the disease rates varied, but postulated two factors: genetics and lifestyle. They found that a gene (apolipoprotein E), known to raise the risk of Alzheimer disease, occurred with equal frequency in the two groups. However, “in the African-Americans the gene is definitely increasing the risk for Alzheimer disease, while in the Nigerian group it doesn’t seem to have an effect,” Dr Frederick W. Unverzagt, a co-author of the study, told the Bulletin. As for possible lifestyle influences, the study found that the Yoruba have a “much lower prevalence” of vascular risk factors — lower cholesterol levels and fewer cases of diabetes and hypertension — than the African-Americans.

“Maybe the incidence numbers can be explained by a gene–environment interaction,” says Unverzagt. “It could be that the ApoE gene is just not activated in certain environments.” Follow-up studies, he says, will examine diet, activity levels, and social engagement. “If factors like diet are found to influence the disease,” says Unverzagt, “the public health implications could be tremendous. If modifying such factors could delay the onset of Alzheimer by 5 to 10 years, you could really forestall some of the looming public health problems posed by the disease.”

The study is believed to be the first cross-cultural study of dementia to use the same methodology and the same group of researchers at different sites. Previous studies have compared rates from different countries, but drawing conclusions from such comparisons is often difficult because of methodological differences.

“Such cross-cultural studies are extremely difficult to do,” Dr Denis Evans, director of the Rush Institute for Healthy Aging, in Chicago, commented to the Bulletin. “They’ve done a magnificent job with that. They carried out the same procedures 4000 miles apart. This is very encouraging for people who have thought about doing this sort of work.”

In an accompanying editorial, Dr Lindsay Farrer of the Boston University School of Medicine, Massachusetts, says “preliminary evidence suggests that a high-fat diet may increase the risk of developing” Alzheimer disease and “studies have revealed that [Alzheimer] cases are less active physically than controls in early life.” Currently, though, most experts say that the only established risk factors are genetics and increasing age.

Catherine Dold, Boulder, Colorado, USA

US health care takes a battering

The United States’ health care system fails to deliver consistent, high-quality health care to its citizens, and without a major overhaul the problem will continue, according to a new report from the Institute of Medicine (IOM) of the US National Academies. The report outlines the problems hobbling the country’s health care system and describes changes necessary to fix it.

“The American health care system offers the sophistication of a space station delivered with the efficiency of a third-world post office,” says Dr Lucian L. Leape, a physician at the Harvard School of Public Health and a member of the IOM committee that drafted the report. The report blames “a highly fragmented delivery system that largely lacks even rudimentary clinical information capabilities” for the gap between the calibre of care possible and the quality typically delivered. The committee also criticizes a health care system that “frequently falls short in its ability to translate knowledge into practice and to apply new technology safely and appropriately.”

The shortcomings the committee found aren’t unique to the US. Dr Tessa Tan-Torres Edejer, with WHO’s Global Programme on Evidence for Health Policy, says: “The few data that we have suggest that the same problems exist in just about every country, with some countries relatively worse, and some better off. Inevitably, the countries that look for problems, find them.”

Australia and Mexico are two countries she recalls that conducted recent studies revealing malfunctioning areas of their health care delivery systems. “There are probably many others but these are not reported in the scientific press because they are meant for internal use.”

The problems of the US health care system can’t be resolved without a complete overhaul of the current system, the IOM committee argues. “The current care system cannot do the job. Trying harder will not work. Changing systems of care will.” To this end, the committee established a list of guidelines for improving health care in the US. These include a shift toward patient-focused care. “Right now the system is designed around what doctors can deliver, rather than on the care that patients need,” says Leape. The report says patients must be given greater control over their care, and greater access to current health information.

The report also calls for better communication between health care practitioners. “The big secret about the American health care system is that no-one is in charge,” Leape told the Bulletin. He says the current system consists of separate care systems in the poorest countries.
givers who work as individuals rather than as groups, and this lack of communication means that care is often duplicated or second-rate. The report calls for health care providers to make greater use of information technologies, such as the internet, to better coordinate patient care and increase efficiency. Other priorities include keeping providers informed about current scientific knowledge and providing health care for the nation’s 40 million uninsured citizens.

In addition, the committee urges US government agencies to identify at least 15 of the most common chronic conditions and develop strategies for managing them over the long term. “We need to shift the focus to managing chronic disease instead of merely treating single episodes in isolation,” Leape says. “The obvious question now is: Who is going to make this happen? We’ve asked for the allocation of funds to begin making these changes. But whether that happens or not is a political decision. It’s unclear what will happen in the current political climate.”

WHO’s Tan-Torres Edejer adds that all countries would like to have a health system that provides seamless top-quality service wherever the patient accesses the system, from the family physician to the high-tech hospital. “However, I don’t know of any country that has reached that ideal. Perhaps the US, with its capability and penchant to use management models from other sectors, like the error reporting system in the aviation sector, and to take advantage of the latest technology, has the potential to get close to that ideal. But as the IOM reports, even the US system has still a long way to go.”

Christie Aschwanden, Nederland, Colorado, USA

In Brief

New partnership boosts work on malaria vaccine for children
The pharmaceutical giant GlaxoSmithKline (GSK) has teamed up with the US-based Program for Appropriate Technology in Health (PATH) to develop a malaria vaccine for use in children. PATH will inject US$ 6.7 million into the partnership’s work on the vaccine, which GSK initiated in 1983. The vaccine consists of a malaria parasite protein fused to a fragment of the hepatitis B virus. In a field trial in 1998–99 in West Africa, it conferred short-term protection on adults: about two-thirds of the vaccinated volunteers were protected for up to 8 weeks after vaccination.

Further information from Anne P. Walsh, GSK, Rixensart, Belgium: tel +32 (2) 656 9831; PATH Malaria Vaccine Initiative, Rockville, MD, USA: tel: +1 (301) 770 5377, fax: (301) 770-5322, email: <info@malariavaccine.org>; web site: www.MalariaVaccine.org

Update on depleted uranium tests
A group of experts reported in March to the European Commission that exposure to depleted uranium could not result in detectable damage to human health. Another report, however, issued in the same month by the UN Environment Programme (UNEP), said that although tests had shown “no significant risks... of contamination to air or plants”, depleted uranium ammunition buried in the soil could produce a 10- to 100-fold increase in uranium levels in drinking water that might exceed WHO health standards.

Further information from Melinda Henry, WHO: tel: +41 (22) 791 2535; fax: +41 (22) 791 4858; email <henrym@who.int>; web site: <www.who.int>

Multiple sclerosis and hepatitis B vaccine — no evidence of link
Two large US studies that since 1976 and 1989, respectively, have monitored health-related events in a total of about 140,000 nurses, have found no association between hepatitis B vaccination and the development of multiple sclerosis. Rumours of such a link were mooted several years ago in France and more recently in the US.

Further information from <http://www.nejm.org/content/2001/0344/0005/0327.asp>